This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Source of effectiveness data
The effectiveness data were derived from the STIVORO database and from a review and synthesis of published studies.
Modelling
The authors used a dynamic simulation model to evaluate possible gains in life-years, quality-adjusted life-years (QALYs), and the savings in health care costs that result from a decrease in the incidence of smoking-related diseases due to smoking cessation interventions. The main difference between this model and other models was that this model followed a changing population over time rather than following one cohort of people through time. The prevalence of smoking consisted of three states (never a smoker, current smoker and former smoker), and the cycle of each state equalled one year. The time horizon of the model was 75 years and the start year of the simulations was year 2000. The transition probabilities depended on gender, age and risk factor state (never, current or former smoker). Further details of the model are reported elsewhere (Hoogenveen et al. 1998 , and Feenstra et al. 2001 see ,Other Publications of Related Interest-below for bibliographic details).
Outcomes assessed in the review
The main effectiveness parameters found from the literature were the abstinence rates associated with the different interventions and the percentages of those taking a smoking cessation intervention who were taking the specific interventions. There were numerous other parameters that cannot be reported here.
Study designs and other criteria for inclusion in the review
Data were derived from cohort studies, international randomised controlled trials and Cochrane meta-analyses. No further criteria for inclusion in the review were reported.
Sources searched to identify primary studies
Not reported.
Criteria used to ensure the validity of primary studies
Methods used to judge relevance and validity, and for extracting data
Number of primary studies included
Overall, the authors used 25 primary studies as sources of effectiveness data.
Methods of combining primary studies
No methods were reported. Data from the available studies do not seem to have been combined.
Investigation of differences between primary studies
It appears that differences between the primary studies have not been investigated. 
Results of the review
The percentage of smokers using smoking cessation intervention, as a percentage of the total number of smokers in the country, was 0.026% for TC, 0.36% for MC, 0.66% for MC+NRT, 0.16% for IC+NRT and 0.14% for IC+Bupr.
The 12-month abstinence rates were 3.4% under current practice, 7.6% (95% confidence interval, CI: 6.9 to 8.3) with TC, 7.9% (95% CI: 4.7 to 11.1) with MC, 12.7% (95% CI: 11.9 to 13.5) with MC+NRT, 15.1% (95% CI: 14.1 to 16.1) with IC+NRT, 17.2% (95% CI: 14.0 to 20.4) with IC+Bupr.
Other outcomes ascertained from the literature were reported in full, but are too numerous to be reported here.
Measure of benefits used in the economic analysis
The authors used life-years gained and health utility (QALYs) as measures of benefit in the economic analysis. Both measures were derived from published literature, and the QALY weights used were reported.
Direct costs
The Overhead costs and the cost of assistants were included and were accounted for in each intervention. It was reported that the costs of adverse effects were omitted as they were assumed to be insignificant. The costs and the quantities were reported separately. All quantities of resources used and all costs were derived from published sources and were reported for the price year 2000. As the time horizon of the model was 75 years, the costs were appropriately discounted.
Statistical analysis of costs
The costs were treated deterministically.
Indirect Costs
The indirect costs were not included in the economic analysis.
Currency
Euros (EUR).
Sensitivity analysis
The authors conducted various one-way sensitivity analyses to investigate the impact of variability in the data on the robustness of the results. The parameters tested in the sensitivity analyses were cessation rates, intervention costs, discount rates, time horizon and the percentage of smokers reached who take up an intervention. The 95% CI estimates of cessation rates, and the minimum and maximum prices of intervention costs derived from the literature, were tested in the sensitivity analysis. Different discount rates (0, 3 and 5%) were applied, and a two-way sensitivity analysis was conducted using a 4% discount rate for the costs and a 0% discount rate for the effects. The percentage of smokers that initiated an intervention was varied form 10 to 50% of all smokers. The time horizon was decreased to 20, 30 and 50 years.
Estimated benefits used in the economic analysis
When the intervention was implemented for 75 years, the cumulative discounted life-years gained were 31 
Cost results
For 75 years-implementation, the net value of the intervention at 2000 level prices was EUR 1.7 x10^9 for TC, EUR 0.52 x10^9 for MC, EUR 3.8 x10^9 for MC+NRT, EUR 7.8 x10^9 for IC+NRT, EUR 7.3 x10^9 for IC+Bupr.
Synthesis of costs and benefits
The average cost-effectiveness ratios were calculated. For 75 years-implementation the cost per life-year gained was EUR 1,400 for TC, EUR 1,800 for MC+NRT, EUR 6,200 for IC+NRT, and EUR 4,300 for IC+Bupr. The cost per QALY gained was EUR 1,100 for TC, EUR 1,400 for MC+NRT, EUR 4,900 for IC+NRT, and EUR 3,400 for IC+Bupr.
Minimal GP counselling dominated all other interventions for every implementation period. Assuming 75 yearsimplementation, the MC intervention yielded 330,000 life-years and 410,000 QALYs, and resulted in cost-savings of EUR 1.4 billion. The cost-savings were higher than the intervention costs (EUR 520 million).
The sensitivity analyses demonstrated that the results were sensitive to changes in the effectiveness of the interventions (cessation rates), as they led to changes in the QALYs gained and incidence of smoking-related diseases and thus additional costs. The results were robust to variations in resources used, different time horizons tested, and the percentage of smokers that take up the intervention. The cost-effectiveness ratios were sensitive to different discount rates, with cost-effectiveness becoming less attractive as the discount rate increased.
